180 related articles for article (PubMed ID: 29187463)
1. Multi-Database Description of Primary Splenic Diffuse Large B-Cell Lymphoma.
Byrd KP; Vontela NR; McCullar B; Martin MG
Anticancer Res; 2017 Dec; 37(12):6839-6843. PubMed ID: 29187463
[TBL] [Abstract][Full Text] [Related]
2. Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma.
Olszewski AJ; Ali S
Ann Hematol; 2014 Mar; 93(3):449-58. PubMed ID: 24057925
[TBL] [Abstract][Full Text] [Related]
3. Survival in advanced diffuse large B-cell lymphoma in pre- and post-rituximab Eras in the United States.
Shah BK; Bista A; Shafii B
Anticancer Res; 2014 Sep; 34(9):5117-20. PubMed ID: 25202101
[TBL] [Abstract][Full Text] [Related]
4. Changes in treatment patterns and impact of radiotherapy for early stage diffuse large B cell lymphoma after Rituximab: A population-based analysis.
Haque W; Dabaja B; Tann A; Khan M; Szeja S; Butler EB; Teh BS
Radiother Oncol; 2016 Jul; 120(1):150-5. PubMed ID: 27373911
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of primary splenic diffuse large B-cell lymphoma and role of splenectomy in improving survival.
Bairey O; Shvidel L; Perry C; Dann EJ; Ruchlemer R; Tadmor T; Goldschmidt N
Cancer; 2015 Sep; 121(17):2909-16. PubMed ID: 26096161
[TBL] [Abstract][Full Text] [Related]
6. Addition of Rituximab to Chemotherapy Reduced the Rate of Surgery for Gastric-DLBCL Without Increasing Early Mortality.
Prouet P; Giri S; Wiedower E; Fintel A; Yaghmour G; Lamb EP; Deneve J; Fleming M; Dickson P; Chandler JC; Martin MG
Anticancer Res; 2017 Feb; 37(2):813-817. PubMed ID: 28179335
[TBL] [Abstract][Full Text] [Related]
7. Trends in Survival of Patients with Primary Gastric Diffuse Large B-Cell Lymphoma: An Analysis of 7051 Cases in the SEER Database.
Liu PP; Xia Y; Bi XW; Wang Y; Sun P; Yang H; Li ZM; Jiang WQ
Dis Markers; 2018; 2018():7473935. PubMed ID: 30410635
[TBL] [Abstract][Full Text] [Related]
8. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database.
Castillo JJ; Winer ES; Olszewski AJ
Am J Hematol; 2014 Mar; 89(3):310-4. PubMed ID: 24273125
[TBL] [Abstract][Full Text] [Related]
9. Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era.
Starr AG; Caimi PF; Fu P; Massoud MR; Meyerson H; Hsi ED; Mansur DB; Cherian S; Cooper BW; De Lima MJG; Lazarus HM; Gerson SL; Jagadeesh D; Smith MR; Dean RM; Pohlman BL; Hill BT; William BM
Hematology; 2017 Aug; 22(7):405-411. PubMed ID: 28105889
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological features of splenic tumours of lymphoid tissue.
Chen DB; Shen DH; Yang SM; Fang XZ
Pathol Res Pract; 2018 Dec; 214(12):1952-1958. PubMed ID: 30087035
[TBL] [Abstract][Full Text] [Related]
11. Similar prognosis of transformed and de novo diffuse large B-cell lymphomas in patients treated with immunochemotherapy.
Sorigue M; Garcia O; Baptista MJ; Sancho JM; Tapia G; Mate JL; Feliu E; Navarro JT; Ribera JM
Med Clin (Barc); 2017 Mar; 148(6):243-249. PubMed ID: 28038857
[TBL] [Abstract][Full Text] [Related]
12. Role of radiation therapy in primary breast diffuse large B-cell lymphoma in the Rituximab era: a SEER database analysis.
Liu PP; Wang KF; Jin JT; Bi XW; Sun P; Wang Y; Yang H; Li ZM; Jiang WQ; Xia Y
Cancer Med; 2018 May; 7(5):1845-1851. PubMed ID: 29624913
[TBL] [Abstract][Full Text] [Related]
13. Role of radiation therapy in primary mediastinal large B-cell lymphoma in rituximab era: A US population-based analysis.
Giri S; Bhatt VR; Pathak R; Bociek RG; Vose JM; Armitage JO
Am J Hematol; 2015 Nov; 90(11):1052-4. PubMed ID: 26270899
[TBL] [Abstract][Full Text] [Related]
14. Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab.
Gundrum JD; Mathiason MA; Moore DB; Go RS
J Clin Oncol; 2009 Nov; 27(31):5227-32. PubMed ID: 19770371
[TBL] [Abstract][Full Text] [Related]
15. Comparison of survival outcomes of different treatment modalities for patients with primary splenic diffuse large B cell lymphoma.
Yonghao O; Yongyang W; Siqing Y; Lihua C; Shuju T
Ann Hematol; 2023 Jul; 102(7):1857-1865. PubMed ID: 37188977
[TBL] [Abstract][Full Text] [Related]
16. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
17. Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma.
Williams JN; Rai A; Lipscomb J; Koff JL; Nastoupil LJ; Flowers CR
Cancer; 2015 Jun; 121(11):1800-8. PubMed ID: 25675909
[TBL] [Abstract][Full Text] [Related]
18. Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era.
Perrone S; D'Elia GM; Annechini G; Ferretti A; Tosti ME; Foà R; Pulsoni A
Leuk Res; 2016 May; 44():53-60. PubMed ID: 27030961
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma.
Griffiths RI; Gleeson ML; Mikhael J; Dreyling MH; Danese MD
Cancer; 2012 Dec; 118(24):6079-88. PubMed ID: 22648454
[TBL] [Abstract][Full Text] [Related]
20. Presence of autoimmune disease affects not only risk but also survival in patients with B-cell non-Hodgkin lymphoma.
Kleinstern G; Averbuch M; Abu Seir R; Perlman R; Ben Yehuda D; Paltiel O
Hematol Oncol; 2018 Apr; 36(2):457-462. PubMed ID: 29469175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
